|
Live Q&A hosted by Andy Teasdale
|
|
0
|
183
|
January 30, 2026
|
|
TGA updated Established acceptable intake for nitrosamines in medicines on 29 January 2026
|
|
0
|
425
|
January 29, 2026
|
|
Nitrosamine Drug Substance-Related Impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon Cytochrome P450-dependend metabolic activation-Pub
|
|
2
|
248
|
January 29, 2026
|
|
Sufentanil Nitroso impurity standard
|
|
8
|
252
|
January 29, 2026
|
|
Nitrosation of Inosine-like compounds
|
|
1
|
149
|
January 26, 2026
|
|
If NDSRIs are not detected at end of stability, is small-molecule nitrosamine testing still required?
|
|
5
|
282
|
January 23, 2026
|
|
Nitrosamine Impurities: The Analytical & Regulatory Roadmap (2024-2025)
|
|
0
|
440
|
January 20, 2026
|
|
Approach for N-Nitroso Imatinib Limits: Database vs ICH S9
|
|
5
|
248
|
January 22, 2026
|
|
EMA has updated its AI limits on 01 Aug 2025
|
|
18
|
3214
|
January 21, 2026
|
|
N-nitroso-Impurity C in Metamizol Drug product
|
|
28
|
3105
|
January 21, 2026
|
|
Limit of Common or Small Nitrosamine Impurities in RSM irrespective of any particular MDD
|
|
9
|
375
|
January 21, 2026
|
|
Formation of N-nitroso dabrafenib in the dabrafenib API?
|
|
3
|
163
|
January 21, 2026
|
|
Should we test presence of Amine/ Chloramine in Potable Water and Nitrosamine in Purified Water?
|
|
2
|
268
|
January 20, 2026
|
|
🇹🇷 USP is hosting a user event (and I will be there! 👨🔬)
|
|
4
|
312
|
January 20, 2026
|
|
How to determine the AI limit value and LOQ when MDD is less than 880mg?
|
|
1
|
196
|
January 20, 2026
|
|
🇲🇽 Mexico Nitrosamine Guide published today
|
|
46
|
3759
|
January 16, 2026
|
|
Impact of nitrocellulose-free foil on dry powder product performance and stability
|
|
4
|
287
|
January 15, 2026
|
|
Nitrosamine impurity evaluation in animal health API
|
|
2
|
115
|
January 15, 2026
|
|
🇪🇬 EDA Workshop: Nitrosamine Impurities, Risk Assessment, Control Strategies, and Regulatory Compliance
|
|
3
|
364
|
January 14, 2026
|
|
Deriving safe limits for N-nitroso-bisoprolol by error-corrected next-generation sequencing (ecNGS) and benchmark dose (BMD) analysis, integrated with QM modeling and CYP-docking analysis
|
|
14
|
809
|
January 13, 2026
|
|
🇺🇸 FDA Information Session on Generic Drug Research Needs & Opportunities for FY 2026
|
|
0
|
267
|
January 12, 2026
|
|
Detecting Nitrosamines & Mutagenic Impurities
|
|
0
|
229
|
January 12, 2026
|
|
Happy 2026 Nitroso-warrior!
|
|
5
|
483
|
January 9, 2026
|
|
How to Establish MDD for Creams and Ophthalmic Solutions
|
|
4
|
387
|
January 8, 2026
|
|
Evaluation of Nitrosamine impurities in animal health APIs
|
|
1
|
148
|
January 8, 2026
|
|
Nitrosamine Impurities in Excipients
|
|
11
|
580
|
January 8, 2026
|
|
Liquid medicinal product with lidocaine
|
|
4
|
197
|
January 8, 2026
|
|
👨💻 Quantification of nitrite and nitrate in Crospovidone by ion chromatography
|
|
0
|
410
|
January 7, 2026
|
|
Calling our Risk Assessment Experts
|
|
52
|
1757
|
December 30, 2025
|
|
Limits more than one Nitrosamine?
|
|
45
|
3500
|
December 30, 2025
|